Evotec SE

NASDAQ:EVO

Drug Manufacturers - Specialty & Generic

Healthcare
$1.46 -0.57%

-$0.02 today

Market cap
$518.56M
Beta
1.30
P/E (TTM)
-4.2
EPS (TTM)
-$1.09
52W Low $2.31High $4.42

Volume 0.04M

Average 0.08M

EVO Purchases of Investments

Cash used to buy marketable securities and other investments.

Evotec SENASDAQ: EVO

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments turns negative

Q1 FY2026 purchases of investments was -€4.58M, compared with €0 a year earlier. Trailing-twelve-month purchases of investments was -€7.57M. Over 3 fiscal years it compounded at -66.5% a year.

Context

  • Purchases of investments amounted to 1.8% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Purchases of investments grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly purchases of investments holds near -€4.58M or moves back toward the trailing-twelve-month quarterly average of -€1.89M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€4.58M— QoQ
Last fiscal yearDec 2025
-€13.42M-54.3% YoY
LTMMar 2026
-€7.57M-68.5% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-54.3%——
3-year CAGR-66.5%——
5-year CAGR——
10-year CAGR——

Purchases of Investments history

EUR · from the cash flow

Latest · FY2025
(13.42M) EUR
Year-over-year change
+54.3%

Purchases of Investments vs competitors

How EVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so purchases of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -68.5% is the 6th highest of 8, against a peer median of -19.1%.
  • Purchases of investments amounts to 1.0% of revenue for EVO, versus a peer median of 9.9%.
EVO Competitors
Purchases of Investments for EVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYRESpyre Therapeutics, Inc.LTM Sep 2026$1.01B USD+143.8%+136.5%1114.4%
NVCRNovoCure LimitedLTM Mar 2026$802.32M USD-19.1%-14.2%119.0%
AZTAAzenta, Inc.LTM Sep 2026$375.68M USD-16.8%+16.7%60.4%
SDGRSchrödinger, Inc.LTM Sep 2026$244.18M USD-20.6%+4.9%90.7%
PCRXPacira BioSciences, Inc.LTM Mar 2026$72.66M USD-72.7%-29.2%9.9%
ALVOAlvotechLTM Mar 2026$31.66M USD——5.7%
HROWHarrow Health, Inc.LTM Mar 2026$18M USD——6.7%
TLRYTilray Brands, Inc.LTM Feb 2026$7.69M USD+139.8%—0.7%
EVOEvotec SELTM Mar 2026€7.57M EUR-68.5%-66.5%1.0%
TDOCTeladoc Health, Inc.LTM Mar 2026$1.5M USD-94.5%—0.1%
PHVSPharvaris N.V.LTM Sep 2026€0 EUR———
Peer median (excluding EVO) —-19.1%+4.9%9.9%

Competitors are the stored peer set for EVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income215.51M(175.66M)(83.91M)(196.08M)(99.43M)
Depreciation & Amortization67.61M83.2M92.98M101.62M95.55M
Deferred Income Tax5.07M21.7M3.32M2.1M14.11M
Stock-Based Compensation7.81M9.92M9.63M5.04M0
Change in Working Capital(2.28M)105.29M(9.94M)(68.21M)(58.4M)
Accounts Receivables(48.03M)(53.68M)00(27.6M)
Inventory(11.65M)(4.41M)00(9.18M)
Accounts Payables31.34M24.55M00(7.02M)
Other Working Capital26.06M138.83M(9.94M)(68.21M)(14.61M)
Other Non-Cash Items(171.47M)161.37M24.37M173.75M39.11M
Operating Cash Flow122.24M205.81M36.44M18.22M(9.06M)
Capital Expenditures(118.94M)(181.35M)(216M)(132.24M)(69.68M)
Acquisitions (Net)(21.09M)(83.82M)(20.16M)42.78M213.76M
Purchases of Investments(123.7M)(355.82M)(48.39M)(29.39M)(13.42M)
Sales of Investments27.25M205.17M260.36M35.67M38.87M
Other Investing Activities(7.38M)3.03M8.22M(2.78M)0
Investing Cash Flow(243.86M)(412.8M)(13.29M)(71.19M)159.86M
Debt Repayment14.77M(53.11M)84.6M(152.07M)(6.96M)
Common Stock Issued404.32M355K00(1.27M)
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(20.67M)(5.39M)(12.63M)(9.35M)(22.71M)
Financing Cash Flow398.43M(58.15M)71.96M(161.42M)(30.93M)
Effect of Forex Changes(66K)(19.04M)644K9.87M28.46M
Net Change in Cash276.75M(284.17M)95.75M(204.52M)148.32M
Free Cash Flow3.29M24.46M(179.56M)(114.02M)(78.74M)

Evotec SE

NASDAQ:EVO

Intrinsic Alpha fair value

Locked

Current Price

$1.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.